Selected article for: "Convalescent plasma and Ebola virus"

Author: Koepsell, Scott A.; Winkler, Anne M.; Roback, John D.
Title: The Role of the Laboratory and Transfusion Service in the Management of Ebola Virus Disease()()
  • Cord-id: jrfbnalc
  • Document date: 2016_11_16
  • ID: jrfbnalc
    Snippet: The Ebola outbreak that began in 2013 infected and killed record numbers of individuals and created unprecedented challenges, including containment and treatment of the virus in resource-strained West Africa as well as the repatriation and treatment for patients in the United States and Europe. Valuable lessons were learned, especially the important role that the laboratory and transfusion service plays in the treatment for patients with Ebola virus disease (EVD) by providing data for supportive
    Document: The Ebola outbreak that began in 2013 infected and killed record numbers of individuals and created unprecedented challenges, including containment and treatment of the virus in resource-strained West Africa as well as the repatriation and treatment for patients in the United States and Europe. Valuable lessons were learned, especially the important role that the laboratory and transfusion service plays in the treatment for patients with Ebola virus disease (EVD) by providing data for supportive care and fluid resuscitation as well as the generation of investigational therapies such as convalescent plasma (CP). To provide treatment support, laboratories had to evaluate and update procedures to ensure the safety of laboratory personnel. Because there is no licensed EVD-specific treatment, CP was used in more than 99 patients with only 1 possible severe adverse event reported. However, given the biologic variability inherent in CP as well as the small number of patient treated in a nonrandomized fashion, the efficacy of CP in the treatment of EVD remains unknown.

    Search related documents:
    Co phrase search for related documents
    • abo compatible and acute respiratory syndrome: 1, 2
    • abo compatible plasma and acute lung injury: 1, 2
    • abo compatible plasma and acute respiratory syndrome: 1, 2
    • acid testing and active disease: 1
    • acid testing and active infection: 1, 2, 3, 4
    • acid testing and active infection patient: 1
    • acid testing and acute lung injury: 1, 2
    • acid testing and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acid testing and additional testing: 1, 2, 3, 4, 5, 6
    • active disease and acute lung injury: 1
    • active disease and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active disease and additional testing: 1
    • active disease and additional variable: 1
    • active disease and adjustment activity: 1
    • active disease patient and acute respiratory syndrome: 1, 2, 3
    • active infection and acute lung injury: 1, 2, 3, 4, 5
    • active infection and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active infection and additional testing: 1, 2
    • active infection patient and acute respiratory syndrome: 1, 2, 3, 4, 5